

Correction: EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

In this article (Clin Cancer Res 2009;15:5753–61), which was published in the September 15, 2009 issue of *Clinical Cancer Research* (1), the disclosure of potential conflicts of interest statement was incorrect. The correct statement is, as follows:

Dorine Bax, Nathalie Gaspar, Suzanne Little, Lynley Marshall, Lara Perryman, Marta Viani-Pereira, Raisa Vuononvirta, Swee Sharp, Jorge Reis-Filho, Andrew Pearson, Paul Workman, and Chris Jones are or were employees of The Institute of Cancer Research, which has a commercial interest in the development of PI3K inhibitors and operates a rewards-to-inventors scheme. Paul Workman and his team have been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma, and intellectual property arising from the program has been licensed to Genentech. Paul Workman was a founder of, consultant to, Scientific Advisory Board member of, and stockholder in Piramed Pharma, which was acquired by Roche, and was formerly an employee of AstraZeneca.

Reference

1. Bax DA, Gaspar N, Little SE, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009;15:5753–61.

Published OnlineFirst 11/3/09.
© 2009 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-09-2835